• Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

    المصدر: Nasdaq GlobeNewswire / 01 يونيو 2023 07:00:00   America/New_York

    WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present a company overview at 4:00 PM ET on June 8 at the Jefferies Healthcare Conference, taking place June 7th-9th, 2023, in New York, NY.

    A link to the live webcast of the presentation will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.

    About Werewolf Therapeutics:
    Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance both WTX-124 and WTX-330 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. To learn more visit www.werewolftx.com.

    Investor Contact:
    Josh Rappaport
    Stern IR
    212.362.1200
    Josh.Rappaport@sternir.com

    Media Contact:
    Amanda Sellers
    VERGE Scientific Communications
    301.332.5574
    asellers@vergescientific.com

    Company Contact:
    Ellen Lubman
    Chief Business Officer
    Werewolf Therapeutics
    elubman@werewolftx.com


    Primary Logo

شارك على،